GLP-1 pill vs injection: How do they compare for Canadians?

Résumé détaillé
As a new oral weight loss drug is on the horizon for Canadians, how does the pill compare to injectable GLP-1 drugs? We asked the experts.
The rapid growth in the GLP-1 medication market got yet another boost this week as Health Canada approved Eli Lilly’s once-a-day oral pill Foundayo for weight loss.
Eli Lilly has already cemented its position as market leader, with sales of its drugs Zepbound and Mounjaro skyrocketing.
As Foundayo is on the horizon for Canadians, how does the pill compare to injectable GLP-1 drugs?
On Wednesday, Eli Lilly’s Foundayo was approved for adults with obesity as well as those who are overweight and have at least one related medical problem, such as high blood pressure or sleep apnea.
In addition to promoting and maintaining weight loss, the pill is also approved to help treat Type 2 diabetes.
The increasing availability of oral GLP-1 medication helps provide more options for patients, said Dr. Hertzel Gerstein, professor of medicine at McMaster University and Hamilton Health Sciences.
“Choice is good, and the more options that we have, the more any particular person can find the thing that works for them,” said Gerstein, who is a diabetes researcher and a doctor.
There is another GLP-1 pill — Novo Nordisk’s Rybelsus — already on the market in Canada, but it is only approved for Type 2 diabetes management and not for weight loss.
The active ingredient in Foundayo is orforglipron, a non-peptide GLP-1 receptor agonist.
Début de l'article, extrait de Global News. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (globalnews.ca)


